12:00 AM
 | 
Jan 12, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TPI ASM8: Phase II data

In the double-blind, European Phase II TPI ASM8-205 trial in 18 patients with mild to moderate asthma, inhaled TPI ASM8 once daily for 14 days missed the primary endpoint of an allergen-induced maximum decrease in FEV1 for late asthmatic response vs. placebo. The company...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >